OPRX vs. PRG, GDRX, CTOS, CRTO, TIXT, EVH, MPLN, YEXT, MEG, and RDWR
Should you be buying OptimizeRx stock or one of its competitors? The main competitors of OptimizeRx include Aaron's (PRG), GoodRx (GDRX), Custom Truck One Source (CTOS), Criteo (CRTO), Telus Digital (TIXT), Evolent Health (EVH), MultiPlan (MPLN), Yext (YEXT), Montrose Environmental Group (MEG), and Radware (RDWR). These companies are all part of the "business services" industry.
OptimizeRx vs. Its Competitors
Aaron's (NYSE:PRG) and OptimizeRx (NASDAQ:OPRX) are both small-cap business services companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, earnings, institutional ownership, dividends, risk, profitability, media sentiment and valuation.
97.9% of Aaron's shares are owned by institutional investors. Comparatively, 76.5% of OptimizeRx shares are owned by institutional investors. 3.2% of Aaron's shares are owned by insiders. Comparatively, 5.6% of OptimizeRx shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Aaron's has a net margin of 8.53% compared to OptimizeRx's net margin of -9.42%. Aaron's' return on equity of 22.54% beat OptimizeRx's return on equity.
In the previous week, OptimizeRx had 5 more articles in the media than Aaron's. MarketBeat recorded 11 mentions for OptimizeRx and 6 mentions for Aaron's. Aaron's' average media sentiment score of 1.44 beat OptimizeRx's score of 0.84 indicating that Aaron's is being referred to more favorably in the media.
Aaron's has a beta of 1.77, indicating that its share price is 77% more volatile than the S&P 500. Comparatively, OptimizeRx has a beta of 1.2, indicating that its share price is 20% more volatile than the S&P 500.
Aaron's has higher revenue and earnings than OptimizeRx. OptimizeRx is trading at a lower price-to-earnings ratio than Aaron's, indicating that it is currently the more affordable of the two stocks.
Aaron's currently has a consensus target price of $41.00, indicating a potential upside of 15.33%. OptimizeRx has a consensus target price of $11.81, indicating a potential downside of 31.84%. Given Aaron's' higher probable upside, analysts clearly believe Aaron's is more favorable than OptimizeRx.
Summary
Aaron's beats OptimizeRx on 11 of the 16 factors compared between the two stocks.
Get OptimizeRx News Delivered to You Automatically
Sign up to receive the latest news and ratings for OPRX and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding OPRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
OptimizeRx Competitors List
Related Companies and Tools
This page (NASDAQ:OPRX) was last updated on 9/16/2025 by MarketBeat.com Staff
